New Launch23 Jan 2026, 08:22 am
Sun Pharma Receives DCGI Approval for Generic Semaglutide Injection in India for Chronic Weight Management
AI Summary
Sun Pharmaceutical Industries Limited has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity. The product, named Noveltreat, will be launched after the expiry of semaglutide patent in India. The approval follows a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths and will be administered via a prefilled pen for convenient and accurate dosing.
Key Highlights
- Sun Pharma receives DCGI approval for generic semaglutide injection in India for chronic weight management
- Product to be launched under the brand name Noveltreat after the expiry of semaglutide patent in India
- Received approval following a review of a Phase III clinical trial conducted in India
- Product to be available in five dose strengths with a maintenance dose of 2.4 mg once weekly
- Product to be administered via an easy-to-use prefilled pen for convenient and accurate dosing